Roquefort Therapeutics develops first-in-class, patent-protected anti-cancer medicines targeting hard-to-treat cancers through pre-clinical research in the immuno-oncology sector. The company aims to enhance treatment options for patients with resistant cancers by leveraging a scalable R&D model and partnerships with leading academic cancer research centers.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers are resistant to existing therapies, creating a need for new medicines, particularly in the immuno-oncology sector. Developing novel anti-cancer drugs is a complex and costly process, often requiring extensive infrastructure and expertise.
Solution
Roquefort Therapeutics is developing a portfolio of first-in-class, patent-protected anti-cancer medicines focused on treating cancers that are resistant to existing therapies. Their approach leverages pre-clinical research in immuno-oncology, targeting mechanisms to enhance treatment options for patients with hard-to-treat cancers. The company utilizes a scalable and cost-effective R&D model, working with a network of partnerships with leading academic cancer research centers to complement their in-house expertise and laboratory infrastructure. This distributed approach allows for a broader and more effective development strategy.
Target Audience
The primary target audience includes patients with hard-to-treat cancers, as well as pharmaceutical companies seeking to expand their oncology portfolios through partnerships or acquisitions.
Features
- Portfolio of five novel, patent-protected pre-clinical anti-cancer medicines.
- Focus on cancers resistant to existing therapies within the immuno-oncology market.
- Access to a state-of-the-art laboratory facility with clean room, laminar flow cabinets, and cryopreservation infrastructure.
- Distributed R&D model leveraging partnerships with leading academic cancer research centers.